A prospective study consortium for the discovery and validation of early detection markers for ovarian cancer - baseline findings for CA125
Epithelial ovarian cancer (EOC) is a lethal malignancy. Cancer antigen 125 (CA125), the “best” available marker for detecting EOC, has insufficient sensitivity and specificity for earlier-stage disease and is not a meaningful screening tool, motivating the search for further biomarkers. Cancer bioma...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 June 2025
|
| In: |
Clinical cancer research
Year: 2025, Jahrgang: 31, Heft: 12, Pages: 2441-2453 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-24-1845 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-24-1845
|
| Verfasserangaben: | Rudolf Kaaks, Victoria Cooley, Trasias Mukama, Lauren R. Teras, Alpa V. Patel, Giovanna Masala, Marta Crous-Bou, Holly R. Harris, Hilde Langseth, Heljä-Marja Surcel, Nicolas Wentzensen, Kathryn Terry, Naoko Sasamoto, Shelley Tworoger, and Renée Turzanski Fortner |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1939669960 | ||
| 003 | DE-627 | ||
| 005 | 20251029111314.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251029s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-24-1845 |2 doi | |
| 035 | |a (DE-627)1939669960 | ||
| 035 | |a (DE-599)KXP1939669960 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kaaks, Rudolf |d 1960- |e VerfasserIn |0 (DE-588)172809223 |0 (DE-627)697739562 |0 (DE-576)133665518 |4 aut | |
| 245 | 1 | 2 | |a A prospective study consortium for the discovery and validation of early detection markers for ovarian cancer - baseline findings for CA125 |c Rudolf Kaaks, Victoria Cooley, Trasias Mukama, Lauren R. Teras, Alpa V. Patel, Giovanna Masala, Marta Crous-Bou, Holly R. Harris, Hilde Langseth, Heljä-Marja Surcel, Nicolas Wentzensen, Kathryn Terry, Naoko Sasamoto, Shelley Tworoger, and Renée Turzanski Fortner |
| 264 | 1 | |c 15 June 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Veröffentlicht: 13.Juni 2025 | ||
| 500 | |a Gesehen am 29.10.2025 | ||
| 520 | |a Epithelial ovarian cancer (EOC) is a lethal malignancy. Cancer antigen 125 (CA125), the “best” available marker for detecting EOC, has insufficient sensitivity and specificity for earlier-stage disease and is not a meaningful screening tool, motivating the search for further biomarkers. Cancer biomarker discovery is enhanced by “omics” technologies. Discovery studies for EOC biomarkers should be conducted in prediagnosis blood samples from prospective cohorts to maximize the likelihood of identifying markers that can detect disease before usual diagnosis and in earlier disease stage while reducing methodologic biases.Individual cohorts with prediagnosis blood samples have insufficient sample size for such studies. Thus, we established “Prospective Early Detection Consortium for Ovarian Cancer” (“PREDICT”)—a collaboration of nine prospective studies—to assemble a sufficient number of EOC cases with blood samples collected ≤18 months before diagnosis plus controls. The 457 cases and 1,687 controls have circulating CA125 measured using a clinical assay.The discrimination capacity for single CA125 measurements in samples collected <6 months prior to diagnosis was high (AUC; PREDICT overall = 0.92; range across cohorts of nonpregnant individuals = 0.89-0.98) and declined with extended time between blood collection and diagnosis. Between-cohort variability in CA125 levels and predictive performance was observed.Ongoing investigations in PREDICT are evaluating the early detection potential of tumor-associated autoantibodies and miRNAs using CA125 as a benchmark. PREDICT is a well-characterized resource for identifying and validating detection markers for EOC that may then be used in multimodal screening as a complement to CA125 and combined with imaging. | ||
| 700 | 1 | |a Cooley, Victoria |e VerfasserIn |0 (DE-588)1380206812 |0 (DE-627)1939670322 |4 aut | |
| 700 | 1 | |a Mukama, Trasias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Teras, Lauren R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Patel, Alpa V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Masala, Giovanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Crous-Bou, Marta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Harris, Holly R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Langseth, Hilde |e VerfasserIn |4 aut | |
| 700 | 1 | |a Surcel, Heljä-Marja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wentzensen, Nicolas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Terry, Kathryn |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sasamoto, Naoko |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tworoger, Shelley |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fortner, Renée Turzanski |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 31(2025), 12 vom: Juni, Seite 2441-2453 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a A prospective study consortium for the discovery and validation of early detection markers for ovarian cancer - baseline findings for CA125 |
| 773 | 1 | 8 | |g volume:31 |g year:2025 |g number:12 |g month:06 |g pages:2441-2453 |g extent:13 |a A prospective study consortium for the discovery and validation of early detection markers for ovarian cancer - baseline findings for CA125 |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-24-1845 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251029 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1380206812 |a Cooley, Victoria |m 1380206812:Cooley, Victoria |d 50000 |e 50000PC1380206812 |k 0/50000/ |p 2 | ||
| 998 | |g 172809223 |a Kaaks, Rudolf |m 172809223:Kaaks, Rudolf |d 50000 |e 50000PK172809223 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1939669960 |e 4794164203 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"15 June 2025"}],"language":["eng"],"id":{"doi":["10.1158/1078-0432.CCR-24-1845"],"eki":["1939669960"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"13 S.","noteIll":"Illustrationen"}],"person":[{"role":"aut","family":"Kaaks","display":"Kaaks, Rudolf","given":"Rudolf"},{"role":"aut","family":"Cooley","display":"Cooley, Victoria","given":"Victoria"},{"role":"aut","given":"Trasias","display":"Mukama, Trasias","family":"Mukama"},{"role":"aut","given":"Lauren R.","display":"Teras, Lauren R.","family":"Teras"},{"role":"aut","given":"Alpa V.","display":"Patel, Alpa V.","family":"Patel"},{"role":"aut","display":"Masala, Giovanna","family":"Masala","given":"Giovanna"},{"given":"Marta","family":"Crous-Bou","display":"Crous-Bou, Marta","role":"aut"},{"family":"Harris","display":"Harris, Holly R.","given":"Holly R.","role":"aut"},{"role":"aut","family":"Langseth","display":"Langseth, Hilde","given":"Hilde"},{"given":"Heljä-Marja","family":"Surcel","display":"Surcel, Heljä-Marja","role":"aut"},{"role":"aut","given":"Nicolas","display":"Wentzensen, Nicolas","family":"Wentzensen"},{"role":"aut","given":"Kathryn","display":"Terry, Kathryn","family":"Terry"},{"role":"aut","family":"Sasamoto","display":"Sasamoto, Naoko","given":"Naoko"},{"given":"Shelley","display":"Tworoger, Shelley","family":"Tworoger","role":"aut"},{"role":"aut","given":"Renée Turzanski","display":"Fortner, Renée Turzanski","family":"Fortner"}],"title":[{"title":"A prospective study consortium for the discovery and validation of early detection markers for ovarian cancer - baseline findings for CA125","title_sort":"prospective study consortium for the discovery and validation of early detection markers for ovarian cancer - baseline findings for CA125"}],"relHost":[{"id":{"eki":["325489971"],"zdb":["2036787-9"],"issn":["1557-3265"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"role":"isb","display":"American Association for Cancer Research"}],"language":["eng"],"origin":[{"publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedDisp":"1995-","dateIssuedKey":"1995","publisher":"AACR"}],"title":[{"title_sort":"Clinical cancer research","title":"Clinical cancer research"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"31","pages":"2441-2453","text":"31(2025), 12 vom: Juni, Seite 2441-2453","year":"2025","extent":"13","issue":"12"},"disp":"A prospective study consortium for the discovery and validation of early detection markers for ovarian cancer - baseline findings for CA125Clinical cancer research","name":{"displayForm":["American Association for Cancer Research"]},"recId":"325489971","pubHistory":["1.1995 -"],"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"]}],"name":{"displayForm":["Rudolf Kaaks, Victoria Cooley, Trasias Mukama, Lauren R. Teras, Alpa V. Patel, Giovanna Masala, Marta Crous-Bou, Holly R. Harris, Hilde Langseth, Heljä-Marja Surcel, Nicolas Wentzensen, Kathryn Terry, Naoko Sasamoto, Shelley Tworoger, and Renée Turzanski Fortner"]},"note":["Veröffentlicht: 13.Juni 2025","Gesehen am 29.10.2025"],"recId":"1939669960"} | ||
| SRT | |a KAAKSRUDOLPROSPECTIV1520 | ||